CompletedPhase 2NCT03226067
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calliditas Therapeutics AB
- Principal Investigator
- Philippe Wiesel, MDCalliditas Therapeutics AB
- Intervention
- GKT137831(drug)
- Enrollment
- 111 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2017 – 2019
Study locations (30)
- Mayo Clinic, Phoenix, Arizona, United States
- University California Davis, Sacramento, California, United States
- Ventura Clinical Trials, Ventura, California, United States
- Yale School of Medicine, New Haven, Connecticut, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- University of Miami, Miami, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- Jackson Liver and GI Specialist c/o (STAR) LLC, Jackson, Mississippi, United States
- North Shore University Hospital, Manhasset, New York, United States
- NYU Hepatology Associates, New York, New York, United States
- Mount Sinai Health System, New York, New York, United States
- University of Rochester Medical Centre, Rochester, New York, United States
- Dayton Gastroenterology Inc., Beavercreek, Ohio, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03226067 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta